# Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 Diabetes

> **NCT00609856** · PHASE4 · COMPLETED · sponsor: **Skane University Hospital** · enrollment: 36 (actual)

## Conditions studied

- Type 2 Diabetes
- Secondary Drug Failure

## Interventions

- **DRUG:** pioglitazone
- **DRUG:** insulin glargine

## Key facts

- **NCT ID:** NCT00609856
- **Lead sponsor:** Skane University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2008-02-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00609856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00609856, "Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 Diabetes". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00609856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*